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Abstract. While the dietary importance of proteins, essential fatty acids, vitamins and trace 
elements has been well recognised, the role of shadow nutrients, a class of metabolites, which 
are biosynthesized in the body and serve vital functions, such as lipoic acid, choline, inositol, 
taurine and carnitine, has not been adequately appreciated. There are reasons to believe that 
during infancy and in ageing, biosynthesis of these metabolites may be limited. The objective of 
this review is to highlight the essentiality of these nutrients and the need for their 
supplementation in the diets of infants and in elderly people. Provision of shadow nutrients 
where the necessary biosynthetic machinery might not have developed to full stature or might 
have slowed down, is a new concept in nutrition which needs attention.
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Introduction 
 
It is well recognised that certain essential amino acids, vitamins, fatty acids and trace 
elements are needed in the diet (Olson, 1978). It is often taken for granted that the mere 
provision of these essential nutrients in the diet, generates through biosynthesis all of 
the nutrients and intermediary metabolites necessary for normal health. Examples of 
these subsidiary nutrients or shadow nutrients are: nicotinic acid from tryptophan, 
choline from methionine and ethanolamine, vitamin B-12, and biotin endogeneously 
made available by intestinal microorganisms in the gut, carnitine from lysine, inositol 
from glucose, lipoic acid from arachidonic acid and methionine and taurine from 
methionine. While these ‘shadow’ nutrients are produced in sufficient quantities under 
conditions of normal health, it is known that the physiological availability or 
biosynthesis of some of these nutrients is diminished in infancy, during ageing or when 
health is impaired. This is true not only of metabolic intermediates from nutrients, but 
also of neurotransmitters like serotonin, dopamine, epinephrine and acetylcholine 
formed from precursors such as tryptophan, tyrosine and choline (Wurtman, 1981). In 
this review we would like to highlight the nutritional importance of some of these 
factors such as lipoic acid, choline, taurine, inositol and carnitine.
The diet supplied to infants should be designed to bridge the nutritional gap between 
total intra-uterine dependence and complete extra-uterine independence and as such 
 
 
 
Abbreviations used: PD, Pyruvate dehydrogenase; PC, pyruvate carboxylase; CoA, coenzyme A; AcCoA, 
acetyl CoA; AcAcCoA, acetoacetyl CoA; Ac.ch., acetyl choline; CAT, carnitine acyltransferase.
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should contain easily digestible carbohydrates (lactose) and assimilable protein (non- 
coagulable protein) and easily digestible fat (triglycerides containing medium chain 
fatty acids and arachidonic acid). Further, due to the higher extra cellular fluid content, 
the lower ability of an infant’s renal system to produce urine of increased specific 
gravity, the decreased renal clearance capacity and the incomplete development of the 
microsomal system for detoxification, infants need milk to graduate them to adult 
levels of absorption, digestion, assimilation and excretion. Histidine is essential in 
infants whereas in adults, it could be biosynthesized (Snyderman et al., 1959, Holt and 
Snyderman, 1961). Other shadow nutrients which may be limiting in infancy are taurine 
and carnitine. There is danger in considering the infant as a miniature adult in terms of 
nutrition and metabolism.
Similarly, during ageing the metabolic availability of shadow nutrients such as lipoic 
acid, choline and inositol may be decreased either due to reduced rates of synthesis or 
due to the reduced caloric intake and consequent reduction in the ingestion of essential 
ingredients (McGandy et al., 1966, Exton-Smith, 1980, Zeisel et al., 1980). There is 
considerable evidence indicating deceleration during ageing of certain metabolic 
capabilities, such as neuronal acetyl choline synthesis and of inositol from glucose. 
(Campling and Nixon, 1954; Hauser, 1963; Davies and Maloney, 1976).
 
Lipoic acid 
 
Lipoic acid (figure 1) has long been recognised as a vital cofactor in the enzyme 
complexes that catalyse the oxidative decarboxylation of α-keto acids such as pyruvic, 
α-ketoglutaric and branched chain α-keto acids formed during the catabolism of 
branched chain amino acids. Recently the decarboxylation of glycine has been shown to 
require lipoic acid (Fujiwara et al., 1979). A dietary requirement for lipoic acid in 
animals has not been established, nor has a systematic estimation of the lipoic acid 
content in animals during ageing been done. The coenzymic role of lipoic acid in 
transacylation reactions involved in the oxidation of pyruvate is presented in figure 1. 
 
Pyruvate is at the centre of metabolic disposition of substrates from the utilisation of 
proteins and carbohydrates and pyruvic dehydrogenase (PD) (EC 1.2.4.1) is crucial for 
the complete oxidation of glucose and for lipid biosynthesis from glucose (Jungas, 
1970,1971; Halperin, 1970). PD exists in a catalytically active (dephosphorylated) and 
an inactive (phosphorylated) form. Though the content of PD is the same in normal 
and diabetic livers, a larger proportion of the enzyme is in its inactive state in 
streptozotocin induced diabetes in rats (Weinberg and Utter, 1980). Similar reductions 
in active PD has been, reported in perfused rat heart in alloxan diabetes (Kerbey et al., 
1976). Administration of insulin restored the PD activity to normal levels (Hughes et 
al., 1980). We have found that administration of lipoic acid, like insulin treatment 
increases PD activity in the livers of both normal and diabetic rats (table 1). From 
table 2 it can be seen that blood pyruvate levels in alloxan diabetic rats are about 60% 
higher than normal and administration of lipoic acid reduces the elevated blood 
pyruvate in diabetic rats to near normal values in 60 min. We have previously shown 
that biochemical abnormalities such as hypoglycemia, ketonemia, reduction in liver 
glycogen and impaired incorporation of 2- [14C] -acetate into fatty acids in alloxan 
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Figure  1. Lipoic acid 
 
 
Table  1. PD activity in normal and diabetic rat livers.
 
 
All the determinations are means of 6 animals ± S.E. 
a Significantly different from normal at Ρ < 0.01 
b Significantly different from diabetic at Ρ < 0·05 
c Significantly different from diabetic at Ρ < 0·01 
 
diabetic rats were brought to near normal levels by the oral or intraperitoneal 
administration of lipoic or dihydrolipoic acid (Natraj et al., 1984). Lipoic acid content 
in diabetic livers is markedly reduced as compared to its amount in normal liver (Natraj 
et al., 1984). 
In diabetes, along with impairment of pyruvate oxidation (Villee and Hastings, 1949),
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Table  2. Pyruvate levels in blood. 
 
Numbers in the parenthesis indicate the number of animals. The 
values are expressed as mean ± S.E. 
α-Lipoic acid (sodium salt, 10 mg/100g) was injected intra- 
peritoneally as a solution in 0·1 ml water.
* Significantly different from normal Ρ < 0·05. 
** Significantly different from diabetic Ρ < 0·05. 
 
 
increased gluconeogenesis also occurs (Felig et al., 1970; Felig, 1975). Enhanced 
activities of specific gluconeogenic enzymes including cytosolic phosphoenolpyruvate 
carboxykinase (EC 4.1.1.32), fructose 1,6-bisphosphatase (EC 3.1.3.11), glucose 6- 
phosphatase (EC 3.1.3.9) and pyruvic carboxylase (EC 6.4.1.1) have been reported in 
experimental diabetes (Prinz and Seubert, 1964; Filsell et al., 1969; Wilmhurst and 
Manchester, 1970; Chang and Schneider, 1971; Weiss et al., 1971). Mitochondrial 
pyruvic carboxylase (PC) catalyses and initiates gluconeogenesis. Weinberg and Utter 
(1980) using immunochemical techniques, demonstrated that in the livers from 
streptozotocin induced diabetic rats, pyruvic carboxylase activity was twice that in 
normal rat livers when expressed in terms of DNA or body weight; this increase was 
shown to be due to significant increases in the rate of synthesis of the enzyme; whereas 
the rates of synthesis and degradation of PD were not affected. The flux of pyruvate 
carbon atoms through PD and PC and the regulation of these enzyme activities are 
shown in figure 2. It is interesting to note that the high production of acetyl (Ac)- 
coenzyme A-(CoA) and generation of aceto-acetate in diabetes appears to arise not 
from the oxidative decarboxylation of pyruvate but through the increased oxidation of 
fatty acids (Randle et al., 1966). 
It has been proposed that the increased oxidation of fatty acids generates excess 
AcCoA and acetoacetyl CoA (AcAcCoA) which acylate the lipoic acid residues of PD. 
Acylated lipoic acid has been shown to activate PD kinase and thus bring about 
inhibition of PD (Cate and Roche, 1979). The respective metabolic roles of PD and PC 
in various organs are illustrated in table 3. It will be seen from the table that PC is 
crucial for gluconeogenesis, whereas PD is essential for energy production. In diabetes, 
the energy production occurs through the oxidation of fatty acids, and it is well 
recognised that the respiratory quotient is low due to abnormal fatty acid oxidation 
(Randle, 1976). In gluconeogenic organs such as the kidney, PC > PD, but in energy 
consuming organs like the heart PD > PC. Whereas in the normal liver PD and PC are 
finely balanced, in the diabetic liver PC > PD due to the increased demand for glucose 
(Randle et al., 1977).
A decreased glucose tolerance is common in a majority of people during ageing. The 
diminution in the levels of lipoic acid in the liver of diabetic rats and the effectiveness of 
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Figure   2.   Metabolic map in diabetes.
 
 
Table   3.    Regulation of PD and PC in various organs. 
 
 
From Randle et al. (1977). 
 
 
dietary lipoic acid in restoring most of the biochemical abnormalities in diabetes led us 
to consider whether the biosynthesis of lipoic acid is impaired during ageing/diabetes. 
Though lipoic acid is a ubiquitous component in all aerobic organisms and animals, 
most tissues and microorganisms contain only minute quantities of this material. 
Lipoic acid is biosynthesized in Escherichia coli from octanoic acid, hydroxy octanoic 
acid and more efficiently from thiooctanoic acid (White, 1980a,b; 1981). Carreau et al. 
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(1977) have shown that linoleic acid and to a smaller extent oleic acid, act as precursors 
for lipoic acid biosynthesis in the rat. Further, the subcellular location of lipoic acid 
biosynthesis has been shown to be the microsomal fraction in rat liver (Spoto et al., 
1982). However, as shown in table 4, in animal tissues arachidonic acid appears to be the 
most immediate precursor followed by linoleic acid, though octanoic acid incorporated 
into lipoic acid is unlikely to be of physiological significance in view of the unlikely 
occurrence of free octanoic acid in body metabolism. The scheme of biosynthesis of 
lipoic acid from arachidonic acid is given in figure 3.
Figure 3. Biosynthesis of lipoic acid.
 
Further, methionine and cysteine have been shown to be equally effective as sulphur 
donors in the biosynthesis of lipoic acid (Dupre et al., 1980). We have confirmed this 
finding in experiments with diabetic rats. We have further demonstrated that the 
biosynthesis of lipoic acid from linoleic acid is impaired in diabetes and administration 
of insulin enhances this conversion (table 5).
 
Table 5. Incorporation of l-[14C]-linoleic acid into lipoic acid in presence of insulin. 
 
N.D.—not detectable 
Livers were perfused with the labelled precursor for 1 h and incubated for 3 h at room temperature. In 
experiments with insulin, 0·25 i.u./ml of insulin was used in the perfusion medium. Lipoic acid was isolated 
and purified as described in table 4.
 
Essential fatty acids have an insulin sparing effect in diabetes (Houtsmuller et al., 
1981). Is this effect due to an increased biosynthesis of lipoic acid from linoleic acid? 
 
To summarise, the beneficial effects of lipoic acid administration in diabetes have 
been recognised for some time (Pagliaro, 1956; Pagliaro and Furitano, 1956; Greco, 
1957; Brusa and Serafini, 1958; Zueva, 1970). Our observations that lipoic acid acts 
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primarily by enhancing the utilisation of glucose for energy and fatty acid synthesis, 
open up the possibility of using this shadow nutrient as an adjunct in the diet in cases 
where the tolerance to glucose is reduced (e.g. ageing and diabetes).
 
Choline 
 
Choline, a quaternary ammonium base, is distributed ubiquitously in biological 
materials. It is present as an integral part of the membranes of all cells, as a constituent 
of lecithins, plasmalogens and sphingomyelins. Acetylcholine is responsible for the 
transmission of nerve impulses from presynaptic to postsynaptic fibres in the synapses 
of both the sympathetic and parasympathetic nervous systems. Choline is converted 
into acetylcholine by choline acetylase and is hydrolysed by acetylcholinesterase into 
choline and acetate. 
A dietary requirement of choline was first demonstrated by Best and Huntsman 
(1932). Since then choline deficiency has been shown to cause haemorrhagic lesions in 
the kidney and fatty infiltration in the liver in rats and perosis in birds (Griffith and 
Wade, 1939; Jukes, 1940; Hartroft, 1955). From the voluminous literature on choline it 
is evident that it has a lipotropic effect in the liver and increases the formation and 
secretion of chylomicrons in the intestine (Tidwell, 1950; Frazer, 1978). Choline is 
biosynthesized in the body from precursors such as methionine and ethanolamine 
(figure 4) and lecithin via methylation of phosphatidyl ethanolamine (figure 5). Though 
 
Figure  4. Biosynthesis of choline. 
 
 
Figure 5. Biosynthesis of phosphatidyl choline. 
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a specific deficiency of choline has not been demonstrated in humans, in many 
conditions of liver dysfunction, the advantages of feeding choline or its precursors such 
as methionine have been well established (Kautch, 1973; Wallnofer and Hanusch, 1973). 
 
The paradox, however, is that almost all animal cells have the biosynthetic machinery 
to synthesize choline from its precursors, thus rendering dietary supplementation of 
choline or its derivatives somewhat redundant. Further, lecithin (a phospholipid 
containing choline) is largely degraded in the intestine. Despite these observations, 
unequivocal evidence has been obtained demonstrating the beneficial effects of choline 
and lecithin administration in eases of tardive dyskinesia and Huntington’s disease 
(Davis et al., 1976; Tamminga et al., 1977; Growdon et al., 1978).
The hippocampus, a region of the brain known to be essential for the formation of 
new memories, has a particularly large number of cholinergic neurons. Based on the 
observation that muscarinic agonists such as physostigmine (inhibition of acetyl- 
cholinesterase) can improve memory acutely, choline and lecithin have been tried, with 
limited success, in patients with Alzheimer’s type dementia and mild to moderate 
memory disorders (Etienne et al., 1968; Signoret et al., 1978). Further, there is recent 
evidence that the onset of senility is characterized by a decrease in the availability of 
acetyl choline (Ac.ch.) to the neuronal cells in the brain, which seems to be caused by 
the decreased availability of free choline (Gibson and Peterson, 1981). Since choline has 
been shown to diffuse across the blood brain barrier, treatments which raise serum 
choline such as ingesting choline rich foods would provide a way of increasing the 
supply to the brain.
It must be mentioned in this connection that Dysken et al. (1982) in a limited clinical 
study with patients with primary degenerative dementia failed to observe any benefit 
with the administration of lecithin, while earlier reports had claimed significant benefits 
with the administration of choline bitartarate (Fovall et al., 1980; Dysken et al., 1982). 
 
Although lecithin has been recommended and even tried in clinical trials, the 
practicability of including upto 70–100 g/day of lecithin in the diet poses problems. 
 
This raises the question as to what should be the preferred dietary additive for 
enhancing choline availability to the brain for the synthesis of acetylcholine? There is 
considerable evidence indicating a lack of equilibration between choline and lecithin in 
the body. (1) Choline deficiency and its attendant symptoms such as impaired growth, 
haemorrhagic kidneys and fatty liver occur in the face of apparently normal levels of 
lecithin in the liver and the whole organism (Menon and Lucas, 1961). Only the 
administration of choline helps to overcome these problems. (2) Phospholipase D 
(figure 6) is responsible for the hydrolysis of lecithin to free choline. Although an 
enzyme with phospholipase D like activity has been isolated and purified from rat 
brain, the contribution of this enzyme in vivo for the release of free choline from lecithin 
is yet to be established (Taki and Kaufer, 1981). (3) Phospholipase C releases 
phosphoryl choline from lecithin and sphingomyelin and is present in most animal 
tissues. The phosphoryl choline can be cleaved by alkaline phosphatase with the release 
of free choline. However, this method of free choline production would require very 
high levels of lecithin in the tissue (brain) which may be difficult to attain. (4) Lecithin 
in animals is biosynthesized via methylation of phosphatidyl ethanolamine (cephalin) 
rather than from phosphatidic acid and choline, and (5) Lecithin synthesis through 
phosphoryl choline (PC) and α, β diglyceride requires PC synthesis from free choline. 
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Figure   6. Phospholipases. 
 
Thus PC is more involved in the synthesis of lecithin rather than being the source of 
bioavailable choline (Kornberg and Pricer, 1952; Kennedy and Weiss, 1956). 
Further, there is no evidence indicating that the intake of egg yolk containing 0·9 % 
lecithin in humans in anyway protects them against neuropathology or dementing 
illnesses such as Alzheimer's disease or me mory disorders associated with old age. 
However, both positive and negative clinical response to high doses of lecithin in 
Alzheimer disease and primary degenerative dementia have been reported (Etienne et 
al., 1979). It may be stressed that here we are considering the beneficial effects on health 
of supplementing with small amounts, those cofactors which may be lacking in the diet 
and not the therapeutic treatment with choline or its derivatives (Dysken et al., 1982; 
Karczmar, 1979). 
From these considerations it would appear that in order to increase blood levels of 
choline one has to administer free choline or choline esters. Since free choline or even 
phosphoryl choline has a fishy odour and is not acceptable organoleptically for 
incorporation into foods, it is suggested that linoleate or palmitate esters of choline be 
used for this purpose. 
 
Inositol 
 
Like choline, inositol (figure 7) is also well recognised as a vitamin for a number of
organisms. In fact, the effectiveness of hexachlorocyclohexane in killing cockroaches is
due to its inhibitory effect on inositol which is an essential nutrient for insects (Slade, 
1945). It must be emphasized that there is a commonality in the requirements of
vitamins amongst a broad phylum of organisms including bacteria, yeast, insects and 
mammals, and therefore even though a specific inositol deficiency state has not been 
reported in humans, there is no doubt about the need for inositol in human metabolism. 
 
Phosphatidyl inositol, one of the major anionic phospholipids of mammalian cell 
membranes, undergoes stepwise phosphorylation to diphosphoinositide in syn- 
aptosomal fractions in the brain and to triphosphoinositide in erythrocytes and myelin 
membranes (Hawthorne and White, 1975). Hormones such as vasopressin cause rapid 
breakdown of polyphosphoinositides and may exert a primary role in generating 
messenger signals responsible for intracellular Ca2+ mobilization (Thomas et al., 1983). 
Recent evidence suggests that polyphosphoinositides breakdown to phosphatidylino- 
sitol in a number of systems, including muscarinic stimulation of smooth muscle, nerve
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Figure  7. Inositol.
 
endings and parotid gland and thrombin addition to human platlets (Abdel-Latif et al., 
1977; Fischer and Argranoff, 1981; Weiss et al., 1982; Agranoff et al., 1983).
Phosphoinositides form 70 % of the phospholipids of the myelin sheath which is a 
major insulating material in the human nervous system and caters to the brain’s 
conflicting needs for compact size, complex circuitry, rapid signalling and modest use of 
energy. The brain is especially rich in inositol phosphatides (Herken et al., 1958). There 
is evidence to suggest that the biosynthesis of inositol from glucose is decreased as 
animals grow older (Hauser, 1963). Even as lecithin does not contribute to the pool of 
free choline in the body, inositol from phytin does not seem to be available as free 
inositol for the maintenance of body functions.
Inositol has been shown to be a necessary vitamin for growth of mammalian cells 
(Eagle, 1956); stimulation of intestinal peristalsis, in plasma membrane shape 
regulation (Quist and Reece, 1980); and transport of cations across membranes 
especially for the triggering of nerves (Martin et al., 1941; Hawthorne and White, 1975). 
Older nutrition literature has given a significant status to inositol in reducing 
cholesterol esters in the liver (MacFarland and McHenry, 1945, 1948) and it is likely 
that inositol might also promote reduction of blood cholesterol (Rajalakshmi et al., 
1960). Foods containing high amounts of inositol are yeast and tea.
 
Taurine 
 
Taurine (figure 8) is one of the major constituents of the free amino acid pool in all 
mammalian central nervous system tissues. In a mature brain it is usually exceeded in 
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Figure  8. Biosynthesis of taurine. 
 
 
concentration only by glutamic acid and in the developing brain, it is the free amino 
acid present in the greatest concentration. The diversity and magnitude of the functions 
accomplished or influenced by such a chemically simple and inert compound has only 
been emphasized in recent years (Jacobsen, 1980). The major physiological functions of 
taurine are (i) participation in bile conjugation, (ii) osmoregulation, (iii) neurotrans- 
mission and neuroregulation and (iv) membrane stabilization.
Taurine is a constituent of taurocholic acid excreted in the bile of carnivorous 
animals and man. Though taurine is ubiquitously present in most tissues of the body, 
recent evidence has surfaced on the role of taurine in moderating neurotransmission, in 
stimulating retinal metabolism (Mandel et al., 1976; Schmidt et al., 1976), and most 
importantly in preventing cardiac arrhythmia (Akera and Brody, 1976; Grosso and 
Bessler, 1976). Taurine has been shown to confer calcium and potassium stabilising 
capacity on the heart and the brain when circumstances of electrolyte depletion are 
present, thus ensuring cationic and membrane integrity (Akera and Brody, 1976). 
Taurine therapy has been efficacious in experimental models of epilepsy (Barbeau and 
Donaldson, 1973; Van Gelder et al., 1975). There have also been reports of taurine 
depletion in cardiac ischaemia and the ameliorative effect of taurine treatment in such 
conditions (Huxtable and Bressler, 1974a,b). There is an increasing quantum of 
evidence that human infants fed casein-predominant synthetic formulations derived 
from bovine milk may become taurine depleted because the currently available 
products contain little or no taurine (Nayman et al., 1979; Rigo and Senterre, 1977). In 
this context, it is interesting to note that recent studies have demonstrated that in 
infants fed human milk, bile acids predominantly conjugated with taurine during the 
first three months after birth, whereas in infants fed synthetic formulations the bile 
acids conjugated predominantly with glycine (Haber et al., 1978; Watkins et al., 1979). 
Because of its inhibitory neurotransmittary role in the brain and retina and because of 
its importance in the conjugation of bile acids with superior digestive and detergent 
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properties, there is some nutritional logic in introducing taurine as an additive in many 
vegetable products. 
 
Carnitine 
 
Carnitine is a quaternary amine, β-hydroxy, γ-N-tri-methylaminobutyric acid, which is 
an important metabolite in mammalian tissues for the utilization of long chain fatty 
acids as a source of energy (Hoppel, 1982). Carnitine facilitates the transport of fatty 
acids from the cytosol across the mitochondrial membrane via the carnitine acyl- 
transferase (CAT) (EC 2.3.1.7) and translocase systems (figure 9) (Bremer, 1977). 
Carnitine is synthesized in both human liver and kidney from the essential amino acids 
lysine and methionine (figure 10) (Rebouche and Engel, 1980; Tanphaichitr and 
Broquist, 1973). Several other tissues can synthesize the immediate precursor of 
carnitine (γ-butyrobetaine) but lack the last biosynthetic enzyme which hydroxylates γ- 
butyrobetaine to form carnitine. Since cardiac and skeletal muscles cannot synthesize 
 
 
 
 
Figure  9. Fatty acid transport. 
 
 
 
Figure  10 Biosynthesis of carnitine. 
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carnitine, it must be transported into these tissues from the blood stream (Borum 
1981). 
The ability of the rat liver to synthesize carnitine from γ-butyrobetaine increases
from low values in the foetus to adult values on the eighth day after birth. The newborn’s
requirement for carnitine appears to be adequately met by breast milk but there is no 
detectable carnitine in soya protein based formulations, nor is it added to solutions 
used in total parenternal nutrition.
The level of malonyl-CoA determines the rate of fatty acid synthesis, whereas the 
activity of CAT determines the rate of fatty acid oxidation. With high dietary 
carbohydrate, malonyl-CoA concentration and consequently, fatty acid synthesis 
increase, while fatty acid oxidation is suppressed by the inhibition of CAT (figure 9). In 
the fasting animal and in diabetes malonyl-CoA level drops, fatty acid synthesis 
declines and with lower malonyl-CoA levels CAT is no longer inhibited and therefore 
fatty acid oxidation increases (Nutr. Rev., 1980a; McGarry and Foster, 1979; McGarry 
et al., 1978; Broquist, 1982). 
Further, a role for carnitine in the metabolism of branched chain keto acids produced 
by the catabolism of amino acids has been suggested (Nutr. Rev., 1981). Muscle 
weakness and pathology in humans with accompanying myoglobinuria has been 
shown to be due to a relative deficiency of carnitine and can be treated with high 
carbohydrate feeding (Nutr. Rev., 1979b). Low birth weight infants with 
impairment in the lipid and energy utilization may have subnormal carnitine levels in 
the blood (Nutr. Rev., 1980b). There may therefore be a nutritional advantage in 
incorporating carnitine or carnitine containing foods such as meat or meat extracts in 
infant foods. 
Some of these shadow nutrients may be synthesized in the animal body in marginal 
quantities at certain times in the life cycle. There may be an increased need for some of 
these nutrients to be provided specifically in the diets of the elderly or infants. If these 
nutrients are not biosynthesized adequately there would be a need for supplementing 
these exogenously in the diet. Such nutrients may include lipoic acid, choline, taurine, 
inositol and carnitine. 
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